Application of rifamycin-quinolizidone conjugate molecule and pharmaceutically acceptable salt thereof

Abstract

The present invention provides an application of a rifamycin-quinolizidone conjugate molecule shown in formula I and pharmaceutically acceptable salt thereof in preparation of a drug for treating or preventing infections caused by methicillin-resistant, quinolone-resistant, and methicillin and quinolone multidrug resistant Staphylococcus aureus. The rifamycin-quinolizidone conjugate molecule and pharmaceutically acceptable salt thereof provided by the present invention can effectively treat or prevent bacterial infections and diseases caused by methicillin-resistant, quinolone-resistant, and methicillin and quinolone multidrug resistant Staphylococcus aureus, and can reduce spontaneous resistance frequency as compared with a drug combination of rifamycin and quinolones.

1 . A method for treating or preventing infections caused by multiple-resistant  Staphylococcus aureus , comprising:
 administering to a patient in need thereof a rifamycin-quinolizidone conjugate molecule shown in formula I or pharmaceutically acceptable salt thereof.   
       
         
           
           
               
               
           
         
       
     
     
         2 . The method according to  claim 1 , wherein the multiple-resistant  Staphylococcus aureus  comprises methicillin and quinolone multidrug resistant  Staphylococcus aureus , methicillin-resistant  Staphylococcus aureus  or quinolone-resistant  Staphylococcus aureus.    
     
     
         3 . The method according to  claim 1  or  2 , wherein the infections caused by multiple-resistant  Staphylococcus aureus  comprise acute bacterial infections and/or biofilm-associated infections. 
     
     
         4 . The method according to  claim 3 , wherein the acute bacterial infections comprise skin and skin tissue infections, respiratory tract infections or bacteremia. 
     
     
         5 . The method according to  claim 3 , wherein the biofilm-associated infections comprise cardiac valve infections, prosthetic joint infections and catheter related bloodstream infections. 
     
     
         6 . The method according to  claim 2 , wherein the infections caused by multiple-resistant  Staphylococcus aureus  comprise acute bacterial infections and/or biofilm-associated infections.